Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5‐HT₄receptor agonist, following oral and intravenous administration

Abstract

The pharmacokinetics of HTF could be well described by an integrated modelling approach for both p.o. and i.v. data. The derived model will provide guidance in the design of future studies.